Literature DB >> 10720550

A pilus-deficient mutant of Haemophilus ducreyi is virulent in the human model of experimental infection.

J A Al-Tawfiq1, M E Bauer, K R Fortney, B P Katz, A F Hood, M Ketterer, M A Apicella, S M Spinola.   

Abstract

Haemophilus ducreyi expresses fine tangled pili, which are composed predominantly of a major subunit (FtpA). Confocal microscopy showed that an FtpA-specific monoclonal antibody bound to bacteria in biopsy samples obtained from infected human volunteers. To test the role of pili in pathogenesis, an isogenic mutant (35000HP-SMS1) was constructed by insertionally inactivating ftpA. 35000HP-SMS1 did not express FtpA and was nonpiliated but was otherwise identical to its parent, 35000HP. Seven healthy adults were challenged on the upper arm with the isogenic isolates in a double-blinded, escalating dose-response study. Sites inoculated with the mutant produced papules and pustules at rates similar to the rates observed at sites inoculated with the parent. The recovery rate of H. ducreyi from cultures and the histopathology of biopsy samples obtained from pustules inoculated with 35000HP or 35000HP-SMS1 were similar. Although pili are expressed in vivo, FtpA is not required for pustule formation in the human challenge model.

Entities:  

Mesh:

Year:  2000        PMID: 10720550     DOI: 10.1086/315310

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Haemophilus ducreyi associates with phagocytes, collagen, and fibrin and remains extracellular throughout infection of human volunteers.

Authors:  M E Bauer; M P Goheen; C A Townsend; S M Spinola
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Transcription of candidate virulence genes of Haemophilus ducreyi during infection of human volunteers.

Authors:  R E Throm; S M Spinola
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 3.  Immunopathogenesis of Haemophilus ducreyi infection (chancroid).

Authors:  Stanley M Spinola; Margaret E Bauer; Robert S Munson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

4.  Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection.

Authors:  Stanley M Spinola; Cliffton T H Bong; Andrew L Faber; Kate R Fortney; Stacy L Bennett; Carisa A Townsend; Beth E Zwickl; Steven D Billings; Tricia L Humphreys; Margaret E Bauer; Barry P Katz
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

5.  Outer membrane protein DsrA is the major fibronectin-binding determinant of Haemophilus ducreyi.

Authors:  Isabelle Leduc; C Dinitra White; Igor Nepluev; Robert E Throm; Stanley M Spinola; Christopher Elkins
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

6.  Role played by CD4+FOXP3+ regulatory T Cells in suppression of host responses to Haemophilus ducreyi during experimental infection of human volunteers.

Authors:  Wei Li; Klara Tenner-Racz; Paul Racz; Diane M Janowicz; Kate R Fortney; Barry P Katz; Stanley M Spinola
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

7.  Characterization of Haemophilus ducreyi-specific T-cell lines from lesions of experimentally infected human subjects.

Authors:  V Gelfanova; T L Humphreys; S M Spinola
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

8.  Haemophilus ducreyi requires an intact flp gene cluster for virulence in humans.

Authors:  Stanley M Spinola; Kate R Fortney; Barry P Katz; Jo L Latimer; Jason R Mock; Merja Vakevainen; Eric J Hansen
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  A humoral immune response confers protection against Haemophilus ducreyi infection.

Authors:  Leah E Cole; Kristen L Toffer; Robert A Fulcher; Lani R San Mateo; Paul E Orndorff; Thomas H Kawula
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

10.  Experimental infection of human volunteers with Haemophilus ducreyi: fifteen years of clinical data and experience.

Authors:  Diane M Janowicz; Susan Ofner; Barry P Katz; Stanley M Spinola
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.